Veldoreotide - Strongbridge Biopharma

Drug Profile

Veldoreotide - Strongbridge Biopharma

Alternative Names: COR-005; DG-3173; PTR-3173; Veldotide

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Peptor
  • Class Antineoplastics; Cyclic peptides; Eye disorder therapies
  • Mechanism of Action Somatostatin receptor 2 agonists; Somatostatin receptor 5 agonists; Somatostatin receptor subtype 4 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acromegaly
  • No development reported Adrenal cortical hyperfunction; Diabetic retinopathy; Neuroendocrine tumours

Most Recent Events

  • 14 Nov 2017 Strongbridge Biopharma files for patent protection for its PLGA microspheres-based proprietary long-acting formulation for veldoreotide
  • 14 Nov 2017 Strongbridge Biopharma plans preclinical studies for Neuroendocrine tumours
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acromegaly(In volunteers) in Germany (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top